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Introduction {#sec1}
============

Radiotherapy is one of the most important non-surgical modalities for the treatment of cancer. Ionizing radiation used in radiotherapy causes DNA damage because of the production of radicals on cellular DNA and their subsequent oxidation by O~2~ ([@bib5]). However, rapid proliferation of cancer cells and the abnormal tumor vasculature lead to hypoxia ([@bib5], [@bib50]). The lack of O~2~ in the hypoxic regions of tumor tissues enables the reduction of DNA free radicals by sulfhydryl-containing compounds, leading to the restitution of DNA and thus cancer cell survival ([@bib5]). Numerous clinical studies have demonstrated a strong correlation between hypoxia and poor response to radiotherapy ([@bib50]). Hence, different strategies have been developed to increase the O~2~ levels of tumor tissue, including the reduction of O~2~ consumption by metformin, the *in situ* production of O~2~ from H~2~O~2~, and the direct delivery of O~2~ by oxygen carriers ([@bib6], [@bib20], [@bib23], [@bib26], [@bib43], [@bib42], [@bib44]). Perfluorocarbons (PFCs) and hemoglobin are two main classes of blood substitutes used for supplying oxygen to tissues during surgery or therapy ([@bib25], [@bib37]). PFC- or hemoglobin-based nanoparticles have been reported to successfully deliver oxygen to hypoxic tumor sites and improve the efficacy of radio/chemo-therapy ([@bib6], [@bib23], [@bib26], [@bib43], [@bib42]). However, oxygen dissolves in PFC liquids through loose and non-directional van der Waals interactions, and therefore the oxygen dissolution and release from PFCs is directly proportional to the oxygen tension, making it incapable of releasing O~2~ in a hypoxia-dependent manner ([@bib25], [@bib37]). Similarly, hemoglobin as an oxygen-transport protein has a high *p*50 for O~2~ of 26 mm Hg (half-saturated with O~2~ at a pO~2~ of 26 mm Hg), which permits the immediate release of bound O~2~ to normal tissues ([@bib35]). Providing an extra supply of O~2~ to normal cells is undesirable during radiotherapy, since it can lead to increased DNA damage and thus exacerbate radiation-induced side effects ([@bib2]). Hence, new O~2~ carriers are needed for the controlled release of O~2~ to the hypoxic tumor environment.

Myoglobin is a small O~2~-binding protein in vertebrate muscle with a nearly 10-fold lower *p*50 (2.8 mm Hg) than hemoglobin ([@bib35]) that appears well suited for potentially achieving a specific hypoxia-responsive release of O~2~. We thus surmised that the delivery of O~2~-bound myoglobin could be a viable strategy to specifically increase O~2~ levels in hypoxic cancer cells. Nevertheless, the direct delivery of free proteins is challenging owing to their instability and low cell penetration efficiency ([@bib29], [@bib45]). Various materials, like polymers, lipids, inorganic materials, and proteins, have been utilized to manufacture nano/micro-carriers with different chemical and physical properties to protect cargo proteins from degradation and effectively deliver them into mammalian cells ([@bib16], [@bib45]). Compared with other materials, protein-based carriers have certain advantages, including good biocompatibility, biodegradability, and ease of modification ([@bib16], [@bib36]).

We have previously described a protein/peptide delivery platform based on Cry3Aa protein that naturally forms sub-micrometer-sized crystalline inclusions within the bacterium *Bacillus thuringiensis* (*Bt*) ([@bib31], [@bib52]). This Cry platform has shown to considerably improve the stability of its cargo protein in the form of Cry3Aa-cargo fusion protein crystal ([@bib19], [@bib18], [@bib31]). In the present study, we demonstrate that the N-terminal helical domain I of Cry3Aa protein (3ADI) can be used in a related way to promote the formation of 3ADI-myoglobin (3ADI-Mb) fusion protein inclusions directly within *Bt* cells. After coupling with TAT cell penetrating peptide and A549.1 targeting peptide, the resultant 3ADI-myoglobin-TATA549 (3ADI-Mb-TATA549) protein particles exhibited significantly improved cellular uptake and targeting efficiency toward non-small cell lung cancer A549 cells. Notably, the delivery of O~2~-bound myoglobin mediated by the 3ADI-Mb-TATA549 platform increased the intracellular O~2~ levels of hypoxic A549 cells, thereby enhancing their susceptibility to radiation.

Results {#sec2}
=======

Production and Characterization of 3A-Mb and 3ADI-Mb {#sec2.1}
----------------------------------------------------

Our initial studies began with a fusion of myoglobin to the full-length Cry3Aa protein. These Cry3Aa-myoglobin (3A-Mb) fusion protein crystals were produced in *Bt* strain 407-OA ([@bib22]) and isolated by sucrose density gradient centrifugation. SDS-PAGE analysis of the isolated crystals revealed a major band between 75 and 100 kDa, in agreement with the predicted 90.56 kDa molecular weight of the 3A-Mb fusion protein ([Figures S1](#mmc1){ref-type="supplementary-material"} and [S2](#mmc1){ref-type="supplementary-material"}A). The UV-vis absorption spectrum of the 3A-Mb crystals showed a Soret peak at 416 nm and two Q bands at 541 and 579 nm, which are indicative of an O~2~-bound myoglobin (MbO~2~) ([Figure S2](#mmc1){ref-type="supplementary-material"}B). The spectrum was identical to that of the free MbO~2~ protein ([Figure S2](#mmc1){ref-type="supplementary-material"}C).

Having shown that the resultant Cry3Aa-myoglobin fusion crystals retained their O~2~-binding capacity, we then sought to maximize the Mb payload since high loading capacity is a key and desirable feature in drug delivery systems. Park and Federici had previously shown that the N-terminal helical domain I of Cry3Aa (3ADI) was responsible for its crystallization in *Bt* cells ([@bib33]). We thus hypothesized that the fusion of myoglobin to this domain might allow for the production of 3ADI-Mb protein inclusions with a higher Mb payload than 3A-Mb ([Table 1](#tbl1){ref-type="table"} and [Figure S1](#mmc1){ref-type="supplementary-material"}). As predicted, 3ADI-Mb protein inclusions were successfully produced in and purified from *Bt* ([Figures 1](#fig1){ref-type="fig"}A and 1B). Scanning electron micrographs (SEMs) revealed that the purified 3ADI-Mb inclusions were sphere-like particles with an average diameter of 869.22 nm ([Figure 1](#fig1){ref-type="fig"}B). Consistent with the SEM measurements, dynamic light scattering (DLS) analysis indicated that the purified 3ADI-Mb protein particles were uniform (PDI = 0.141) with a mean hydrodynamic diameter of 886.3 nm ([Figure 1](#fig1){ref-type="fig"}C). The average zeta potential of the 3ADI-Mb at −9.94 mV ([Figure 1](#fig1){ref-type="fig"}D) suggested that these bioparticles possessed a slightly negatively charged surface. To ascertain whether the cargo Mb protein was correctly folded within the 3ADI-Mb framework, the O~2~-binding ability of 3ADI-Mb particles was examined by UV-vis absorption. Similar to the spectra of 3A-Mb ([Figure S2](#mmc1){ref-type="supplementary-material"}B) and free MbO~2~ protein ([Figure S2](#mmc1){ref-type="supplementary-material"}C), an intense peak in the Soret region and two Q-band peaks at 542 and 580 nm were also observed for 3ADI-Mb particles ([Figure 1](#fig1){ref-type="fig"}E), thus verifying the presence of bound O~2~.Table 1Myoglobin (Mb) Loading Capacity of 3A-Mb versus 3ADI-MbCry3AaCry3AaDIMb3A-Mb3ADI-MbMolecular weight (kDa)73.1133.3717.3390.5650.83Mb loading capacity19.14%34.09%[^3]Figure 1Characterization of 3ADI-Mb Protein Particle and Its Stability(A) SDS-PAGE analysis of purified 3ADI-Mb protein particles.(B) SEM images of purified 3ADI-Mb showing their uniformity in size and shape. Scale bar, 5 μm.(C) Size distribution of 3ADI-Mb determined by DLS.(D) Zeta potential distribution of 3ADI-Mb.(E) UV-vis absorption spectra of 3ADI-Mb protein particles.(F) Denaturation profiles of Mb protein and 3ADI-Mb protein particles. Data are presented as mean ± standard error of the mean.

Stability of 3ADI-Mb Protein Particles {#sec2.2}
--------------------------------------

One important feature of any drug delivery system, particularly for peptide- or protein-based therapeutics, is the ability of the carriers to confer protection to their cargos. We have previously demonstrated that the framework of Cry3Aa could enhance the stability of its protein cargo ([@bib19], [@bib18], [@bib31], [@bib52]). We therefore hypothesized that the 3ADI-Mb particle should also be able to stabilize its fused Mb partner. To confirm this hypothesis, 3ADI-Mb particles and Mb protein were incubated in PBS at 37°C for 18 h, and their absorbance at 418 nm (Abs~418~) was measured to monitor the protein denaturation ([@bib17], [@bib46]). As shown in [Figure 1](#fig1){ref-type="fig"}F, significant denaturation of the free Mb protein was observed within 4 h post incubation, and after 8 h, the free Mb protein was almost completely denatured. In contrast, the Abs~418~ of 3ADI-Mb particles remained stable during the first 10 h suggesting only minimal denaturation. Thus, similar to Cry3Aa crystals, the 3ADI framework could enhance the stability of its cargo Mb protein, making it well suited for delivering Mb protein to mammalian cells.

Evaluation of the A549.1 Targeting Peptide {#sec2.3}
------------------------------------------

The use of traditional radiotherapy or chemotherapy to treat cancer is frequently limited by its serious side effects that arise from the toxicity of non-selective therapeutics to normal cells or tissues ([@bib1], [@bib2]). Tumor targeting via the coupling of targeting ligands, such as small molecules, antibodies, and peptides, to the surface of drug carriers has been shown to be effective in improving cell recognition and cellular uptake, resulting in enhanced specificity and improved efficacy toward cancer cells ([@bib1], [@bib7]). One advantage of protein-based carriers is the ease of manipulation via genetic modification to accommodate ligands or motifs for specific purposes. Consequently, we appended a known targeting peptide A549.1 ([@bib27]) specific for human non-small cell lung cancer (NSCLC) A549 cells via genetic fusion to the C terminus of 3ADI-GFP to test whether such approach could indeed promote enhanced selectivity toward lung cancer cells. Purified 3ADI-GFP or 3ADI-GFP-A549 particles were incubated with either A549 or normal GES-1 cells for 24 h, and their binding efficiency and specificity were assessed using flow cytometry. As shown in [Figure 2](#fig2){ref-type="fig"}, 3ADI-GFP-A549 particles exhibited preferential binding to A549 cells in comparison with 3ADI-GFP. Intriguingly, the presence of A549.1 peptide appeared to reduce the non-specific binding of 3ADI-GFP particles to the normal GES-1 cells ([Figure 2](#fig2){ref-type="fig"}), further supporting the notion that the A549.1 peptide could aid in facilitating the selectivity of Cry protein-based particles toward A549 cells.Figure 2Evaluation of the Targeting Efficiency of A549.1 Peptide(A) Representative flow cytometric histograms of A549 cells (left) and GES-1 cells (right) treated with 3ADI-GFP or 3ADI-GFP-A549 protein particles.(B) Percentage of fluorescent cells.Data are presented as mean ± standard error of the mean. ∗∗p \< 0.01.

Modification of 3ADI-Mb with Functional Peptides {#sec2.4}
------------------------------------------------

Given the promising results obtained for 3ADI-GFP-A549 particles, we thus proceeded to modify 3ADI-Mb similarly to generate a 3ADI-Mb-A549 construct with potentially enhanced selectivity toward A549 cells. This construct was further modified for cell internalization since previous studies from our laboratory had shown that the related Cry3Aa protein crystals could not be easily taken up by non-phagocytic cells ([@bib52]). Hence, the known cell penetrating peptide TAT ([@bib11], [@bib14]) was introduced upstream of the targeting peptide A549.1 to generate the 3ADI-Mb-TATA549 construct ([Figure S1](#mmc1){ref-type="supplementary-material"}). To assess the impact of these peptides on the functional properties of their respective constructs, 3ADI-Mb, 3ADI-Mb-A549, and 3ADI-Mb-TATA549 particles were produced in *Bt* cells, labeled with Alexa Fluor 488, and their targeting specificities and cellular uptake efficiencies were evaluated. Consistent with the results for 3ADI-GFP-A549, incorporation of the A549.1 targeting peptide enhanced the binding of 3ADI-Mb-A549 and 3ADI-Mb-TATA549 particles toward A549 cells, as verified by flow cytometric analysis ([Figures 3](#fig3){ref-type="fig"}A--3C). Moreover, cells treated with Alexa Fluor 488-labeled 3ADI-Mb-TATA549 particles exhibited significantly higher mean fluorescence intensities ([Figure 3](#fig3){ref-type="fig"}C), suggesting more particles were being delivered to A549 cells. We surmised that the increase was due to the ability of the cell penetrating TAT peptide aiding in the cellular internalization of the 3ADI-Mb-TATA549 particles. This conjecture was confirmed by confocal microscopy, which revealed the facile uptake of 3ADI-Mb-TATA549 particles by A549 cells, but not 3ADI-Mb and 3ADI-Mb-A549 particles, which were found predominately on the membrane surface of the cells ([Figure 3](#fig3){ref-type="fig"}D).Figure 3Cell Targeting and Cellular Uptake of 3ADI-Mb-TATA549 Protein Particles(A) Representative flow cytometric histograms of A549 cells treated with Alexa Fluor 488-labeled 3ADI-Mb, 3ADI-Mb-A549, or 3ADI-Mb-TATA549 protein particles.(B and C) (B) Percentage of fluorescent cells and (C) mean fluorescence intensity of A549 cells with different treatment.(D) Confocal images showing the targeting ability and uptake efficiency of Alexa Fluor 488-labeled 3ADI-Mb, 3ADI-Mb-A549, and 3ADI-Mb-TATA549 particles. Scale bar, 25 μm.Data in 3B and 3C are presented as mean ± standard error of the mean. ∗p \< 0.05; ∗∗p \< 0.01; ∗∗∗p \< 0.001; ∗∗∗∗p \< 0.0001.

3ADI-Mb-TATA549 Particles Enhanced the Radiosensitivity of the Hypoxia-Induced Radioresistant A549 Cells {#sec2.5}
--------------------------------------------------------------------------------------------------------

Since 3ADI-Mb-TATA549 protein particles were significantly more efficient at targeting and entering A549 cancer cells, this construct was further characterized and used for subsequent experiments ([Figure 4](#fig4){ref-type="fig"}). Purified 3ADI-Mb-TATA549 particles retained the red color of Mb, and their purity was confirmed by SDS-PAGE analysis ([Figures 4](#fig4){ref-type="fig"}A and 4B). SEM images showed that purified 3ADI-Mb-TATA549 inclusions were uniform sphere-like particles with an average diameter of 647.71 nm ([Figure 4](#fig4){ref-type="fig"}C). DLS and zeta potential measurements indicated that these particles have an average hydrodynamic diameter of 630.4 nm (PDI = 0.186) and a negatively charged surface (ZP = −10.7 mV) ([Figures 4](#fig4){ref-type="fig"}E and [S3](#mmc1){ref-type="supplementary-material"}A), respectively. The O~2~-bound state of 3ADI-Mb-TATA549 particles was confirmed by its UV-vis absorption spectrum ([Figure 4](#fig4){ref-type="fig"}G) and further verified by its O~2~ dissociation curve generated using a HEMOX analyzer. The O~2~ dissociation curve of 3ADI-Mb-TATA549 protein particles was hyperbolic similar to that of the free Mb protein indicating O~2~ binding ([Figure S4](#mmc1){ref-type="supplementary-material"}). Furthermore, the 3ADI-Mb-TATA549 particles exhibited a *p50* value (2.593 mm Hg) comparable with that of wild-type Mb protein (*p50* = 3.319 mm Hg), suggesting that the ability to bind and release O~2~ of the fused Mb within the particle was not affected. Moreover, stability studies shown that 3ADI-Mb-TATA549 protein particles still exhibited higher stability than free Mb protein after peptide modifications ([Figure S5](#mmc1){ref-type="supplementary-material"}).Figure 4Characterization of 3ADI-Mb-TATA549 and 3ADI-MbH97D-TATA549 Protein Particles(A) Color difference showing the heme binding to 3ADI-Mb-TATA549, but not 3ADI-MbH97D-TATA549 particles.(B) SDS-PAGE analysis of 3ADI-Mb-TATA549 (lane 1) and 3ADI-MbH97D-TATA549 (lane 2) particles. The asterisk indicates the protein bands of these two particles.(C and D) SEM images of (C) 3ADI-Mb-TATA549 and (D) 3ADI-MbH97D-TATA549 protein particles. Scale bar, 2 μm.(E and F) Size distributions of (E) 3ADI-Mb-TATA549 and (F) 3ADI-MbH97D-TATA549 protein particles determined by DLS.(G and H) UV-vis absorption spectra of (G) 3ADI-Mb-TATA549 and (H) 3ADI-MbH97D-TATA549 particles.

In preparation for studies of the 3ADI-Mb-TATA549-mediated delivery of O~2~ to A549 cells, a construct 3ADI-MbH97D-TATA549 harboring a H97D mutation in its Mb domain was produced to be used as a background control to eliminate any possible particle effects. This H97D Mb mutation has been reported to promote heme dissociation ([@bib17]) and thus loss of O~2~-binding ability. DLS analysis of the purified 3ADI-MbH97D-TATA549 protein inclusions showed similar size (hydrodynamic diameter of 655.1 nm) and surface charge (ZP = −10.6 mV) compared with their wild-type counterparts ([Figures 4](#fig4){ref-type="fig"}D, 4F, and [S3](#mmc1){ref-type="supplementary-material"}B and [Table S1](#mmc1){ref-type="supplementary-material"}). However, unlike the wild-type 3ADI-Mb-TATA549, these particles did not possess the red color associated with heme binding, suggesting their loss of heme ligand and therefore the inability to bind O~2~ ([Figures 4](#fig4){ref-type="fig"}A and 4H).

To validate the 3ADI-Mb-TATA549-mediated cellular delivery of O~2~, A549 cells were incubated with free Mb protein, 3ADI-MbH97D-TATA549 or 3ADI-Mb-TATA549 particles at 37°C under 1.5% O~2~ (hypoxia) for 6 h. The relative intracellular O~2~ level was determined using the Hypoxia Green Reagent for Flow Cytometry (Thermo Fisher), which is fluorogenic at low O~2~ levels but non-fluorescent under normoxia. As indicated by flow cytometric analysis ([Figures 5](#fig5){ref-type="fig"}A--5C, [Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}), under hypoxia (1.5% O~2~), the 3ADI-Mb-TATA549-treated group contained significantly less hypoxic cells and decreased fluorescence compared with those of the other groups, including the no-treatment control group, thus confirming the successful delivery of O~2~ by the 3ADI-Mb-TATA549 particles. Furthermore, the supply of O~2~ by 3ADI-Mb-TATA549 was dose dependent, providing the support for its ability to store and deliver O~2~ ([Figures 5](#fig5){ref-type="fig"}D--5F). Notably, free Mb protein was unable to increase the intracellular O~2~ level of A549 cells under hypoxia ([Figures 5](#fig5){ref-type="fig"}A--5C, [Tables S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}), presumably due to its inability to penetrate A549 cells and its instability in aqueous solution ([Figure 1](#fig1){ref-type="fig"}F). Similar results were also observed when the experiments were conducted under 0.5% O~2~, further confirming the effectiveness of 3ADI-Mb-TATA549 particles in O~2~ delivery ([Figure S6](#mmc1){ref-type="supplementary-material"}).Figure 53ADI-Mb-TATA549 Particles Increased the Intracellular O~2~ Levels of Hypoxic A549 Cells(A) Merged flow cytometric histograms showing the decreased fluorescence intensity (more O~2~) of 3ADI-Mb-TATA549-treated hypoxic A549 cells.(B) Percentage of hypoxic A549 cells exposed to different treatments.(C) Mean fluorescence intensity of hypoxic A549 cells exposed to different treatments.(D) Merged flow cytometric histograms of the hypoxic A549 cells treated with different concentrations of 3ADI-Mb-TATA549 particles.(E) Corresponding bar graphs of 5D showing the percentage of hypoxic cells.(F) Mean fluorescence intensity illustrating the dose-dependent effects of 3ADI-Mb-TATA549 particles on the O~2~ levels of hypoxic A549 cells.Data are presented as mean ± standard error of the mean. ns: no significant difference; ∗p \< 0.05; ∗∗p \< 0.01; ∗∗∗p \< 0.001.

Having verified that 3ADI-Mb-TATA549 particles were effective in increasing the O~2~ level in hypoxic cells, we next analyzed their impact on the susceptibility of A549 cells to radiation. A colony-forming assay was first conducted to verify the protective effect of hypoxia on A549 cells. Cells were incubated either under normoxic (21% O~2~) or hypoxic conditions (1.5% O~2~) for 6 h and then irradiated and re-seeded for colony formation. The surviving fraction (SF) of cells under normoxia after 4 Gy radiation was around 0.04, whereas the SF of cells under hypoxia was 0.27, confirming the increased radioresistance of the hypoxic cells ([Figure 6](#fig6){ref-type="fig"}A). The effect of 3ADI-Mb-TATA549 was subsequently investigated by treating A549 cells with 800 nM Mb protein, 3ADI-MbH97D-TATA549 or 3ADI-Mb-TATA549 particles, and then incubating at 37°C under hypoxia (1.5% O~2~) for 6 h, followed by a single dose of irradiation at 4 Gy. As shown in [Figures 6](#fig6){ref-type="fig"}B and 6C, the 3ADI-Mb-TATA549-treated cells (SF = 0.17) after exposure to 4 Gy radiation formed significantly fewer colonies compared with the control group (SF = 0.29). Notably, neither free Mb protein (SF = 0.29) nor the mutant 3ADI-MbH97D-TATA549 (SF = 0.28) was able to enhance the susceptibility of hypoxic A549 cells to radiation ([Figures 6](#fig6){ref-type="fig"}B and 6C).Figure 6Effective Delivery of O~2~ by 3ADI-Mb-TATA549 Particles Enhanced the Susceptibility of Hypoxia-Induced Radioresistant A549 Cells(A) Surviving fractions of A549 cells with or without exposure to radiation under normoxia and hypoxia. Hypoxic cells were significantly more radioresistant than normoxic cells.(B) Representative images showing the colony formation of hypoxic A549 cells treated with 800 nM Mb protein, 3ADI-MbH97D-TATA549 or 3ADI-Mb-TATA549 protein particles after 4 Gy irradiation.(C) Quantitative measurements of corresponding surviving fractions of A549 cells in 6B.Data are presented as mean ± standard error of the mean.ns: no significant difference; ∗∗p \< 0.01; ∗∗∗p \< 0.001; ∗∗∗∗p \< 0.0001.

Radiation-induced DNA damage initiates cell death mainly by apoptosis ([@bib9], [@bib39]). Therefore, to confirm whether the reduced colonies observed for the 3ADI-Mb-TATA549-treated cells was accompanied by an increase in apoptosis, the caspase-3/7 activity of hypoxic A549 cells was measured for the different constructs following irradiation. As expected, cells treated with 3ADI-Mb-TATA549 particles exhibited the highest apoptosis ratio (19.64% apoptotic cells) and caspase-3/7 activity ([Figure S7](#mmc1){ref-type="supplementary-material"}). These results reaffirmed the ability of 3ADI-Mb-TATA549 to effectively deliver O~2~ to cells and thereby enhance the sensitivity of radioresistant hypoxic A549 cells to radiotherapy.

Discussion {#sec3}
==========

The monomeric heme protein myoglobin is expressed predominantly in skeletal and cardiac muscles where it was believed to function solely as an oxygen reservoir, binding O~2~ under aerobic conditions and releasing it to mitochondria for cellular respiration under hypoxia ([@bib13], [@bib32]). In recent years, the ectopic expression of myoglobin in non-muscle tissues as well as cancer cell lines and tumors has been reported ([@bib3], [@bib10], [@bib21], [@bib28]). Expression profiling of tumors from patients with head and neck squamous cell carcinoma has revealed that myoglobin expression is associated with better prognosis ([@bib28]). The non-canonical tumor suppressor function of myoglobin has also been confirmed by preclinical investigations on breast cancer and lung cancer cells ([@bib4], [@bib13], [@bib21]).

Ample evidence suggests that hypoxia promotes tumor progression and is a potent barrier to effective cancer therapy; thus, overcoming hypoxia is a key element to the successful application of any cancer treatment. In the study by Michieli and colleagues, A549 cells transduced with lentiviral vector-encoding Mb gene exhibited reduced hypoxia and when transplanted into mice delayed tumor engraftment ([@bib13]), suggesting the potential of Mb\'s ability to conquer tumor hypoxia.

In this study, we took advantage of the high binding affinity of myoglobin for O~2~ and its ability to release O~2~ under hypoxia to act as an O~2~ carrier targeting hypoxia-induced radioresistant cancer cells. We report the successful proof-of-concept results on the use of our Cry platform to deliver MbO~2~ to hypoxic A549 cancer cells as a means to increase the intracellular O~2~ levels and thereby enhance their sensitivity to radiation.

One major hurdle to the broad application of protein therapeutics is their instability ([@bib47]). We have previously reported the advantages of the Cry3Aa platform in the immobilization of enzymes and for the delivery of antimicrobial peptides due to its exceptional stability ([@bib19], [@bib18], [@bib31], [@bib52]). Herein we demonstrated the utilization of the crystal-forming domain of Cry3Aa protein to directly produce 3ADI-Mb protein particles in *Bt* cells for myoglobin delivery. Myoglobin within the 3ADI-Mb framework was proven to be more stable than free myoglobin protein. Furthermore, the Cry platform is amenable to modification. Active tumor targeting has shown to improve the specificity of traditional nanomedicine ([@bib7], [@bib8]). Efficient coupling of functional ligands to the delivery vehicle is therefore crucial to achieve this aim. By simply using recombinant fusion protein technology, the 3ADI platform was further equipped with a cell penetrating peptide TAT and a targeting peptide A549.1 at its C terminus, and the resultant 3ADI-Mb-TATA549 protein particles were directly produced in *Bt*, thus demonstrating the versatility of this platform. It should be noted that the TAT and A549.1 sequences were important in facilitating the facile uptake of 3ADI-Mb-TATA549 protein particles into cells. Since this Cry platform is protein based, the surface-exposed cysteine and lysine residues could also be utilized for chemical conjugation of different ligands, like small molecules, polymers, and peptides.

Numerous studies have shown that many nano/microparticles possess intrinsic properties that induce cytotoxicity in mammalian cells ([@bib12], [@bib34]), which might also affect their radiosensitivity ([@bib24], [@bib40], [@bib53]). Thus, to eliminate any possible effects arising from the particle, rather than the delivered O~2~, we made a 3ADI-MbH97D-TATA549 construct in which His97 of myoglobin was mutated to aspartate to destabilize heme binding, and in turn O~2~ binding ([@bib17]). Unlike 3ADI-Mb-TATA549 particles, delivery of the 3ADI-MbH97D-TATA549 particles to hypoxic A549 cells had minimal effect on the intracellular O~2~ levels and radiosensitivity ([Figures 5](#fig5){ref-type="fig"} and [6](#fig6){ref-type="fig"}). These results provide convincing support that 3ADI-Mb-TATA549 protein particles enhance radiotherapy under hypoxia due to its ability to deliver O~2~ to hypoxic cancer cells, and not from any particle effects.

Going forward, the next step would be to evaluate the *in vivo* efficacy of 3ADI-Mb-TATA549 particles on a mouse model. To ascertain whether the observed SF decrease ([Figure 6](#fig6){ref-type="fig"}C) is sufficient to justify a therapeutic pursuit of this construct on animals or the clinic, we have examined some related studies that reported both *in vitro* and *in vivo* results of radiation. In the work by Grimes et al., nimesulide (Nim) was used to improve the radiation treatment against A549 cells ([@bib15]). Results from their *in vitro* clonogenic assay showed that the SFs of untreated control and 300 μM Nim group were around 0.4 and 0.2 upon 4 Gy radiation, respectively ([@bib15]). Consistent with their *in vitro* results, a significant delay of tumor growth was observed for the Nim and radiation combination group compared with that of the radiation-only group in animal models ([@bib15]). A similar correlation can also be found in the studies by Wolfe et al., in which the SFs of cells treated with goserelin-conjugated gold nanorods (gAuNRs) or PEGylated AuNRs (pAuNRs) upon 4 Gy radiation are around 0.18 and 0.32, respectively ([@bib51]). Their *in vivo* results on a mouse xenograft model indicated that the gAuNRs with lower SF significantly improved radiotherapy compared with pAuNRs ([@bib51]). In our studies, the SFs of untreated CTL and 3ADI-Mb-TATA549 group were 0.29 and 0.17, respectively, the difference between which is comparable with those reported by the aforementioned studies.

In addition to the clonogenic assay, we have conducted cellular apoptosis assay to investigate the apoptotic effects of the treatment and to corroborate the results of the colony-forming assay. The 3ADI-Mb-TATA549 treatment increased the percentage of caspase 3/7-activated cells from 10% to 20% upon 4 Gy radiation (a 2-fold change) ([Figure S7](#mmc1){ref-type="supplementary-material"}). This 2-fold increase is comparable with that reported by Liu and colleagues, who used perfluorocarbon-loaded hollow Bi~2~Se~3~ nanoparticles to enhance radiotherapy ([@bib43]). Their *in vitro* experiments showed that the nanoparticles + radiation treatment led to a nearly 2-fold increase in DNA damage compared with radiation alone, and with this degree of difference *in vitro*, they were able to further demonstrate in mouse model that their nanoparticles together with radiation resulted in significant reduction in tumor volume ([@bib43]).

We believe all these data should allow us to expect a promising outcome for our construct in animals. Nevertheless, the *in vitro* results, including the SF difference we observed between the CTL and 3ADI-Mb-TATA549, were conducted under specific experimental conditions, and may not be necessarily related to *in vivo* performance. The parameters, including the doses of both particle and radiation, need to be optimized on mice prior to conducting *in vivo* efficacy evaluation experiment.

Another potential concern for the *in vivo* application of the 3ADI-Mb-TATA549 particles is their near-micron size. It has been reported that small nanoparticles (\<100 nm) preferentially accumulate in tumor sites by enhanced permeability and retention (EPR) effects, owing to the tumor\'s leaky vasculature. However, this concept of passive targeting to tumor tissues through EPR effects is still controversial ([@bib7]). A recent study showed that inter-endothelial gaps are not responsible for the transport of nanoparticles into solid tumors, whereas up to 97% nanoparticles enter tumors via active transcytosis crossing the tumor endothelium ([@bib41]). This means that the trans-endothelial transport, which is related to the uptake efficiency of particles, is essential to tumor penetration. Given the notable uptake of the 3ADI-Mb-TATA549 particles by mammalian cells, we believe it is possible for them to reach the tumor tissues. There are indeed some studies showing that microparticles could accumulate in tumor ([@bib49]). At present, we think the main hurdle preventing our particles from successful tumor penetration via intravenous (i.v.) injection might be the rapid clearance by the reticuloendothelial system. Some strategies, including PEGylation and modification of particles with "self" peptides, have been developed to abolish the recognition and uptake of particles by phagocytes and therefore prolong their circulation time ([@bib38], [@bib48]). Given the ease of surface modification of the Cry platform, these approaches can be utilized to improve the *in vivo* performance of our Mb-containing particles for systemic administration. Besides, i.v. injection is not always necessary; microparticles have their own advantages for pulmonary delivery since they can penetrate deep into the lungs ([@bib30]).

In summary, we have found that the N-terminal helical domain I of Cry3Aa was sufficient to promote the formation of protein inclusions in *Bacillus thuringiensis* cells that stabilized its cargo myoglobin. The addition of tumor targeting and cell penetrating peptide sequences to the Cry-myoglobin fusion protein construct significantly improved cell targeting and uptake efficiency, resulting in increased oxygenation of radioresistant hypoxic cells, thus making them more susceptible to radiation. Our results suggest that the targeted delivery of O~2~-bound myoglobin to increase the intracellular oxygen levels in tumors could be a viable strategy to overcome radioresistance.

Limitations of the Study {#sec3.1}
------------------------

Further *in vivo* investigations on animal models would be needed to study the 3ADI-Mb-TATA549-mediated delivery of O~2~ to tumor tissues and its efficiency in improving cancer radiotherapy.

Resource Availability {#sec3.2}
---------------------

### Lead Contact {#sec3.2.1}
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